Journal
CANCER IMAGING
Volume 21, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40644-021-00426-2
Keywords
Cutaneous cancer; Immunotherapy; FDG-PET; PERCIST1.0; RECIST1.1
Funding
- NHMRC Investigator Grant [APP1175929]
Ask authors/readers for more resources
In patients with advanced cutaneous squamous cell carcinoma receiving cemiplimab for more than 10 months, there was a discordance between complete metabolic response rates on FDG-PET and RECIST1.1. FDG-PET/CT may be useful for clarifying the depth of response in patients treated with immunotherapy for CSCC.
Background The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months. Methods This was a single-centre retrospective study of 15 patients treated with cemiplimab for advanced CSCC who had CT/MRI and FDG-PET/CT at > 10 months to assess metabolic treatment response. The median age was 73 years (range 55-84) and 93% were male. RECIST1.1 and PERCIST1.0 tumor responses were evaluated by blinded readers. Results Seventy-three percent (11/15) (95%CI 44.9, 92.2%) achieved a CMR on PET. Of these 11, on RECIST1.1 there was one complete response, 9 partial responses and one stable disease. Conclusions In patients on cemiplimab for > 10 months, there was discordance between CR rates on FDG-PET versus RECIST1.1. FDG-PET/CT may have utility for clarifying depth of response in patients treated with immunotherapy for CSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available